SOBI Stocks: Price Chart, History & Competitors

[[ data.name ]]

[[ data.ticker ]]

[[ data.price ]] [[ data.change ]] ([[ data.changePercent ]]%)

Low: [[ data.low ]]

High: [[ data.high ]]

Sell
[[ data.bid ]] [[ data.spreadText ]] Buy
[[ data.ask ]]

TRADE NOW

About

History

Competitors

About

History

Competitors

Swedish Orphan Biovitrum, often known as SOBI (SOBI.SE), is a prominent speciality healthcare company based in Europe. With a market capitalization of 64.25 billion SEK as of July 5, 2023, the company specializes in providing innovative treatments for rare diseases.

Founded in 2001 through a merger between Biovitrum and Swedish Orphan International, it has its headquarters in Stockholm, Sweden. The company's mission is to improve the lives of patients with rare diseases by bringing forward innovative therapies.

It went public and started trading on the US100 Stockholm stock exchange. Since then, the company has grown to become a global leader in its field, focusing on areas such as Hematology, Immunology, and Specialty Care.

Swedish Orphan Biovitrum has seen a varied journey since its inception. The company's share price has experienced notable fluctuations, reflecting the intricacies of the healthcare industry and general market trends.

In the past five years, its stock price has hit significant highs and lows. The stock reached a peak of 299.60 SEK in September 2018, showcasing a period of robust performance and investor confidence. Conversely, it bottomed out at 127.10 SEK in May 2021 amidst challenging market conditions.

Such fluctuations emphasize the importance of utilizing analytical tools when considering trading this stock. Traders may find tools such as Bollinger Bands, Pivot Points and Inverted Hammer useful. These tools may provide insights into potential future price movements. Additionally, conducting a fundamental analysis of the company's financial health and market position may offer investors valuable context for making informed trading decisions.

Before trading Swedish Orphan Biovitrum stock, it's important to consider its key competitors within the pharmaceutical industry. They include:

AstraZeneca (AZN.SE) is a multinational biopharmaceutical company with a similar focus on rare diseases. Their research and product portfolio could significantly impact SOBI's market share.
Pfizer (PFE.US), another global pharmaceutical giant, is also a considerable competitor. Known for its extensive range of healthcare products, Pfizer's moves in the industry may influence SOBI's performance.
Sanofi (SASY.PA), a French multinational pharmaceutical company, is also critical to observe. Sanofi's robust presence in the European market, where SOBI is based, may directly affect SOBI's stock.

Understanding these competitors' strategies and market movements may provide deeper insights into the industry trends, helping investors make more informed decisions about trading Swedish Orphan stock.

Premium Standard

Swap long	[[ data.swapLong ]] points
Swap short	[[ data.swapShort ]] points
Spread min	[[ data.stats.minSpread ]]
Spread avg	[[ data.stats.avgSpread ]]
Min contract size	[[ data.minVolume ]]
Min step size	[[ data.stepVolume ]]
Commission and Swap	Commission and Swap
Leverage	Leverage
Trading Hours	Trading Hours

* The spreads provided are a reflection of the time-weighted average. Though Skilling attempts to provide competitive spreads during all trading hours, clients should note that these may vary and are susceptible to underlying market conditions. The above is provided for indicative purposes only. Clients are advised to check important news announcements on our Economic Calendar, which may result in the widening of spreads, amongst other instances.

The above spreads are applicable under normal trading conditions. Skilling has the right to amend the above spreads according to market conditions as per the 'Terms and Conditions'.

Trade Now

Trade [[data.name]] with Skilling

All Hassle-free, with flexible trade sizes and with zero commissions!*

Trade 24/5
Minimum margin requirements
No commission, only spread
Fractional shares available
Easy to use platform

*Other fees may apply.

FAQs

Does SOBI pay dividends?

+ -

The Board of Directors of Swedish Orphan Biovitrum AB (SOBI) has proposed not to pay a dividend. Instead, they recommend that the company's retained profits be carried forward. This decision might reflect a strategic move to reinvest in the business or preserve capital for future opportunities.

What are the major factors affecting SOBI's stock price?

+ -

SOBI's stock price is primarily influenced by these five factors:

Financial Performance: Quarterly and annual earnings, revenue growth, profit margins, and management guidance significantly impact investor sentiment.
Clinical Trials and Approvals: Success or failure in clinical trials and regulatory approvals from bodies like the FDA and EMA can cause substantial stock price fluctuations.
Market Trends and Sentiment: The performance of the biotech sector and broader market trends, along with overall investor sentiment, affect SOBI’s stock.
Regulatory Changes: Changes in healthcare policies, drug pricing regulations, and patent laws can influence SOBI’s financial outlook and market position.
Competition and Strategic Moves: Advances by competitors, strategic partnerships, mergers, acquisitions, and the strength of SOBI’s product pipeline are crucial determinants of its stock value.

Who are the major shareholders of SOBI?

+ -

The major shareholders of Swedish Orphan Biovitrum AB (SOBI) as of June 28, 2024, are:

Investor Aktiebolag
Morgan Stanley Smith Barney LLC, W9
Fjärde AP-fonden
State Street Bank And Trust Co, W9
AMF Fonder & Pension

These entities represent the top five shareholders based on the percentage of shares they hold.

Why Trade [[data.name]]

Make the most of price fluctuations - no matter what direction the price swings and without capital restrictions that come with buying the underlying asset.